Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...

“Although fundus autofluorescence is the gold standard ... Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection ...

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and ... paired images to compare ultrawide field fundus autofluorescence (FAF) imaging with ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Geographic atrophy is a complex disease ... And just like we can’t replace brain cells if they’re lost, retinal cells don’t grow back when they die. But there’s some evidence that we ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... characterised by the loss of photoreceptors and retinal pigment epithelial (RPE) cells in the central ...

In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.Imaging confirms the ...

Dublin, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The "Geographic Atrophy Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. This report will prove invaluable to leading ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...